Last reviewed · How we verify
IOPAMIDOL
At a glance
| Generic name | IOPAMIDOL |
|---|---|
| Drug class | Radiographic Contrast Agent [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
Common side effects
- Pain
- Hot flashes
- Burning sensation
- Nausea
- Warmth
Serious adverse events
- Anaphylaxis
- Cardiopulmonary arrest
- Myocardial infarction
- Ventricular fibrillation
- Circulatory collapse
- Pulmonary edema
- Seizure
- Coma
- Transient blindness
- Compartment syndrome following extravasation
Key clinical trials
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (PHASE1)
- Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy (PHASE2)
- ISOVUE Comparative Trial (NA)
- Thyroid Function of Pediatric Subjects Following Isovue® Administration (PHASE4)
- PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease
- Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis (NA)
- Adenosine Contrast CorrELations in Evaluating RevAscularizaTION (PHASE4)
- Dynamic Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IOPAMIDOL CI brief — competitive landscape report
- IOPAMIDOL updates RSS · CI watch RSS